Navigation Links
Genocea Reports Positive Initial Phase 1/2a Results for GEN-003, its Pioneering Therapeutic Vaccine Candidate for the Treatment of Herpes Simplex Virus-2 (HSV-2), at ICAAC 2013
Date:9/12/2013

003 please visit www.clinicaltrials.gov.

About GEN-003   
GEN-003 is a first-in-class T cell vaccine intended to reduce the transmission risk and clinical symptoms of herpes simplex virus type 2 (HSV-2). GEN-003 is designed to induce a balanced B cell (antibody) and T cell immune response and includes fragments of ICP4 and gD2 antigens, as well as the proprietary adjuvant, Matrix-M™, licensed from Novavax, Inc. The adjuvant is a novel saponin-derived product that has demonstrated a B and T cell immunostimulatory profile in previous clinical studies.  For more information about GEN-003, please visit http://www.genocea.com/pipeline/hsv-2-faq.html.

About HSV-2   
Herpes simplex virus type 2 (HSV-2) is a sexually transmitted disease that is estimated to affect more than 500 million people worldwide. In the U.S., an estimated 50-60 million people are affected. HSV-2 infection can cause recurring, painful genital sores and, due to the stigma associated with this disease, can affect patients' ability to form and maintain relationships. No vaccine is currently approved to prevent or treat the disease.  

About Genocea   
Genocea Biosciences Inc. is harnessing the power of T cell immunity to develop the next generation of vaccines. T cells are increasingly recognized as a critical element of a protective immune response to a wide range of infectious disease pathogens, but are difficult to target using traditional vaccine discovery methods. Genocea is uniquely able to identify protective T cell antigens in humans exposed to a pathogen using ATLAS™, its proprietary technology platform that mimics the human immune response, potentially improving the effectiveness of vaccine candidates and significantly reducing the time needed to create them. Genocea's pipeline of novel T
'/>"/>

SOURCE Genocea Biosciences Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genocea Biosciences Selected To Present Late-Breaking Oral Presentation At ICAAC 2013
2. Genocea Publishes Preclinical Data For Investigational Vaccine Candidate For HSV-2
3. Industry Veteran Katrine Bosley Joins Genocea Biosciences Board Of Directors
4. Omeros Reports Additional Positive Results from OMS824 Program
5. S&P Capital IQ Initiates Coverage on Epigenomics AG in Standard & Poors Factual Stock Reports
6. CorMedix Reports Receipt of European Patent Office Decision to Allow Prosl Patent to Proceed in European Union
7. Market Research Reports: Biologics, Biosimilars, Bioseparation Systems for Biopharmaceutical Markets
8. South East Asia Medical Device Market Reports
9. CIVETS Medical Device Market Reports
10. Central Europe and Baltic States Medical Device Market Reports
11. Northen Europe Medical Device Market Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... , Nov. 24, 2014 Luoxis ... (NYSE MKT: AMPE), today announced the presentation of ... Diagnostic System as a broadly applicable and robust ... in the body in response to injury, illness, ... performed in collaboration with Luoxis, academic and pharmaceutical ...
(Date:11/24/2014)... Nov. 24, 2014 The Female Health Company ... investor conference call to discuss its operating results for ... 2014 on Tuesday, December 2, 2014 at 11:00 a.m. ... its operating results earlier the same day. ... conference call by dialing 1-877-374-8416 (international participants dial 1-412-317-6716) ...
(Date:11/24/2014)... , Nov. 24, 2014  GlySens Incorporated announced ... million dollar grant from the National Institute of Diabetes ... the National Institutes of Health (NIH).  The grant is ... second generation ICGM™ long term implantable glucose monitoring system.  ... and enrollment is expected to begin before the end ...
Breaking Medicine Technology:Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 2Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 3Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 4Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 5The Female Health Company To Report FY2014 Operating Results on Tuesday, December 2, 2014 2GlySens Incorporated Awarded $2 Million Grant from the National Institutes of Health 2
... with Durezol Dosed Prior to Surgery, TAMPA, ... held ophthalmic-focused biopharmaceutical company, announced,today that Durezol(TM) (difluprednate ... was approved by the U.S. Food and,Drug Administration ... for the treatment of inflammation and pain associated ...
... MEETING, Pa., Oct. 6 Genaera,Corporation (Nasdaq: GENR ... trial of trodusquemine (MSI-1436), Genaera,s lead drug candidate,for the ... a novel,inhibitor of PTP1B, a validated molecular target that ... to normalize glucose and decrease,appetite. In the study, MSI-1436 ...
Cached Medicine Technology:Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 2Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 3Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 4Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 5Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 2Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 3Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 4
(Date:11/24/2014)... November 24, 2014 Mental health ... day. They break up families, ruin careers, and ... hope for those that suffer,” says Hardy ... is showing that our specialized nutritional treatments can ... appear on “Mind Over Matter”, the premiere episode ...
(Date:11/24/2014)... Gersowitz Libo & Korek, P.C., a leading national ... recognition in the 2015 Edition of U.S. News-Best Lawyers list ... unique combination of quality law practice and breadth of legal ... and especially grateful to our clients whose continued support of ... said Jeff S. Korek, senior partner at Gersowitz Libo ...
(Date:11/23/2014)... a well-known wedding dress manufacturer, has unveiled its new collection ... now offered at deeply discounted prices, up to 75 percent ... 15. The main purpose of the promotion is to expand ... are ideal options for ladies who are eager to look ... new mint cocktail dresses are very beautiful; they are made ...
(Date:11/23/2014)... Pro Ace Care, a renowned Vancouver hot water ... providing an 8 year warranty on its selected hot water ... up due to the impending winter season, it was important ... premium service that the company provides. As a result, Pro ... Wood and Bradford hot water tanks. , “Every installer ...
(Date:11/23/2014)... Locks-Magnetic.com, a notable magnetic locks maker, has released ... products are available at low rates up to 30% ... the new emergency doors. The emergency door adopts fireproof ... from several colors. All of the products are top-quality ... is not as easy as many people think. ...
Breaking Medicine News(10 mins):Health News:Nutritional Mental Health Treatment Featured on Access Health Airing on Lifetime Television® 2Health News:Nutritional Mental Health Treatment Featured on Access Health Airing on Lifetime Television® 3Health News:U.S. News-Best Lawyers “Best Law Firms” Names Gersowitz Libo & Korek P.C. a 2015 Tier 1 Ranking Firm 2Health News:Trendy Long Black Evening Gowns Now Provided By iFitDress.com 2Health News:Pro Ace Care Now Gives 8 Year Guarantee on Selected Vancouver Hot Water Tanks 2
... its patient care and billing like Tesco and Toyota to ... be improved by regularizing the movement of patients from Accident ... ,Services like redesigning, making improvements in healthcare, and giving ... Toyota group of companies, which needs to be copied by ...
... has stated, that it suspects that ‘Pneumonic plague’ is responsible ... according to preliminary test results// that it has conducted. The ... set up to treat patients. They also explained that the ... lack of security ,in the area. ,The outbreak ...
... of postgraduate students at Tshwane University of Technology (TUT) ... inch//. No, this is not revenge on your husband ... method to fight obesity. ,Department of sport ... Andrew McKune said that the group of 40 students ...
... resorted to the strike against OBC reservation in educational institutions, ... // to doctors for the strike period was not a ... no pay. If court orders to release the salaries, we ... to protests by medicos at the AIIMS for not getting ...
... Peace, Vijay Amritraj, has launched a charity that will ... ,The UN estimates that about 5.5 million ... a fraction is getting treatment despite the country's pharmaceutical ... ,Launching the `Amritraj Foundation' yesterday, the 53-year old sportsman, ...
... today said it has allotted 61,716 equity shares upon conversion ... FCCB holders. // ,The committee of directors at ... five each of the company at a premium of Rs ... each, the company informed the Bombay Stock Exchange., ,Consequently, ...
Cached Medicine News:
The Calcitonin ELISA is intended for the quantitative determination of Calcitonin in human serum....
... exclusively distributed by Medtronic, sets the ... intra-operative imaging with surgical navigation in ... is one of the most comprehensive ... Exceptional image quality from a low-field ...
Microwell EIA for detection of Calcitonin...
Mircrowell EIA for detection of Intact PTH...
Medicine Products: